文献速递妇科

可操作的自发性抗体反应拮抗卵巢癌恶性进展

Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
PubMed 文献 · Gynecol Oncol · 2023-04-28

研究从卵巢透明细胞癌、子宫内膜样卵巢癌和子宫内膜瘤样本中分离B细胞并制备抗体,筛选出包括SDCBP在内的共有靶点;在荷瘤免疫缺陷小鼠中给予α-SDCBP IgG4可显著缩小肿瘤体积;作者认为自发性抗体反应可产生可测量的免疫压力,利用肿瘤来源抗体开发免疫治疗值得进一步研究。

要点

  • 共鉴定出9种同时被IgA和IgG识别的可及蛋白,包括SDCBP。
  • α-SDCBP IgG4在OVCAR3、TOV21G和RMG-I荷瘤小鼠中较对照无关IgG4显著减小肿瘤体积。
  • 作者认为自发性抗体反应产生次优但可测量的抗肿瘤免疫压力。

核心结论

  • 自发性抗体反应对卵巢癌恶性进展产生次优但可测量的免疫压力。
  • 利用肿瘤来源抗体开发新型免疫治疗值得进一步研究。

研究设计与样本

  • 从冷冻保存的透明细胞卵巢癌(CCC,n=2)、子宫内膜样卵巢癌(EC,n=2)和子宫内膜瘤(n=2)样本中分离B细胞,活化后经EBV永生化。
  • 从B细胞上清纯化抗体,用于覆盖大部分人类蛋白质组的筛选阵列。
  • 靶点按可及性(跨膜或分泌蛋白)、在子宫内膜异位症和癌症中的表达以及同时存在IgA和IgG反应进行优先排序。
  • 聚焦靶向促肿瘤的syndecan结合蛋白(SDCBP)的抗体以展示抗肿瘤活性。
  • 用免疫印迹和qPCR评估卵巢癌细胞系、子宫内膜异位症细胞系及肿瘤样本中SDCBP表达。

主要发现

  • 在所有样本中鉴定出9种同时被IgA和IgG识别的可及蛋白,包括在多种组织学类型卵巢癌中表达的SDCBP。
  • 在OVCAR3(HGSOC)、TOV21G和RMG-I(CCC)荷瘤小鼠中,给予α-SDCBP IgG4较对照无关IgG4显著减小肿瘤体积。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出利用肿瘤来源抗体开发新型免疫治疗值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To demonstrate that shared antibody responses in endometriosis and endometriosis-associated ovarian cancer spontaneously antagonize malignant progression and can be leveraged to develop future immunotherapies. METHODS: B cells from cyopreserved clear cell ovarian carcinoma (CCC, n = 2), endometrioid ovarian carcinoma (EC, n = 2), and endometriomas (n = 2) were isolated, activated, and EBV-immortalized. Antibodies were purified from B cell supernatants and used for screening arrays containing most of the human proteome. Targets were prioritized based on accessibility (transmembrane or secreted proteins), expression in endometriosis and cancer, and concurrent IgA and IgG responses. We focused on antibodies targeting tumor-promoting syndecan binding protein (SDCBP) to demonstrate anti-tumor activity. Immunoblots and qPCR were performed to assess SDCBP expression in ovarian cancer and endometriosis cell lines and tumor samples. Recombinant IgG4 was generated using the variable heavy and light chains of dominant B cell receptors (BCRs) reacting against the extracellular domain of SDCBP, and used in in vivo studies in human CCC- and high-grade serous ovarian carcinoma (HGSOC)-bearing immunodeficient mice. RESULTS: Nine accessible proteins detected by both IgA and IgG were identified in all samples - including SDCBP, which is expressed in ovarian carcinomas of multiple histologies. Administration of α-SDCBP IgG4 in OVCAR3 (HGSOC), TOV21G and RMG-I (CCC) tumor-bearing mice significantly decreased tumor volume compared to control irrelevant IgG4. CONCLUSIONS: Spontaneous antibody responses exert suboptimal but measurable immune pressure against malignant progression in ovarian carcinomas. Using tumor-derived antibodies for developing novel immunotherapeutics warrants further investigation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Handley KF, Mehta S, Martin AL, et al. Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma. Gynecol Oncol. 2023. PMID: 37121178. doi:10.1016/j.ygyno.2023.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。